What You Will Learn

Please join Carterra at our upcoming symposium in San Francisco, CA. You will spend the day learning about high-throughput drug discovery and antibody therapeutics with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

New methods in antibody discovery, DELs and PROTACs
Innovations using HT-SPR for drug discovery
Challenging assay formats, such as membrane targets and rapid binders
Strategies to streamline characterization workflows
Best practices in experimental design and analysis

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Agenda
8:45am – 9:00am	Arrive and Check-in
9:00am – 9:30am	Networking and Coffee/Tea
9:30am – 9:45am	Symposium Begins—Welcome
9:45am – 10:30am	Bill Harriman, PhD, SVP, Antibody Discovery, OmniAb Keynote Address — Use of high throughput antibody characterization to validate novel transgenic animal platforms
	Abstract: Engineered animals designed to produce human sequence antibodies can be evaluated and compared via antibody repertoire analysis at the nucleic acid level, however this approach does not capture antibody specificity profiles and “functional diversity” that may be present at the paratope level. We have generated over 20 different genetic configurations during the past decade, and have routinely evaluated the corresponding immune repertoires through the functional analysis of panels of antigen-specific mAbs using high throughput epitope binning and kinetics analysis. This type of characterization is also critical downstream, in workflows focused on hit expansion and antibody optimization that leverage deep phenotypic screening, NGS datasets, and structural modeling methods.
10:30am – 11:00pm	Dan Bedinger, PhD, Head, Application Sciences, Carterra Discovery and characterization of multi-specific antibodies: New capabilities and workflow
	Abstract: Selection of bi- and tri-specific binders often require the screening of large combinatorial sample sets derived from panels of single domain binders. The Carterra LSA platform makes analyzing the binding properties of these molecules straightforward and requires minimal amounts of mAb sample and antigen. The affinity of the binders to the targets can be measured in several assay formats and used to verify the independence and activity of each binding site for hundreds of clones. Along with the binding kinetics and specificity measurements, the LSA enables large scale epitope binning to ensure diverse sets of clones are being carried forward to functional evaluation.
11:00am – 11:30am	Break and Networking
11:30pm – 12:00pm	Kathryn Hastie, PhD, Instructor, Ollmann Saphire Lab, La Jolla Institute for Immunology Potent, omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before omicron emergence
	Abstract: Therapeutic antibodies are an important tool in the arsenal against coronavirus infection. However, most antibodies developed early in the pandemic have lost most or all efficacy against newly emergent strains of SARS-CoV2, particularly those of the Omicron lineage. Here, we report the identification of a panel of vaccinee-derived antibodies that have broad-spectrum neutralization activity. Structural and biochemical characterization of the three broadest-spectrum antibodies reveal complementary footprints and differing requirements for avidity to overcome variant-associated mutations in their binding footprints. Together, these studies highlight the resilience and vulnerabilities of SARS-CoV-2 antibodies and provide road maps for further development of broad-spectrum therapeutics.
12:00pm – 1:00pm	Lunch and Networking
1:00pm – 1:30pm	Matthew Greving, PhD, VP, Machine Learning and Platform Technologies, iBio High-throughput SPR to screen and train machine learning designed antibody libraries
	Abstract: Antibody discovery efficiency and quality can be enhanced with machine learning. A lack of high-quality activity data at a scale sufficient to test and train models is a major limitation in the integration of machine learning and antibody discovery. We will present the use of high throughput Carterra LSA binding screens to test activity and accuracy of machine learning designed antibody libraries. In addition, we will present the use of high throughput Carterra LSA binding screens to train a machine learning model that predicts high-affinity antibodies for a target.
1:30pm – 2:00pm	Sam Zeng, PhD, Senior Research Scientist, OmniAb Application of Ni-NTA LSA sensor chip in measuring Picobody™ binding affinity
	Abstract: A subset of antibodies generated by cows feature ultralong CDRH3s with unique stalk/knob structures that are capable of binding deeply recessed or cryptic epitopes on target proteins that may be inaccessible to classical antibodies. Such antibodies not only can be expressed in the context of full antibodies or Fabs, but also in the form a 4-6kD “picobody.” These alternate forms can present challenges for characterization. Measuring the bona-fide, 1:1 binding affinity of naturally multivalent antibody-antigen interactions is facilitated by recombinant protein engineering and assay designs. The Ni-NTA surface enables captured kinetics assays with His-tagged antigens immobilized as ligands and recombinant antibodies as analytes while overcoming hurdles in surface regeneration.
2:00pm – 2:30pm	Break and Networking
2:30pm – 3:00pm	Dalton Markrush, Scientist, Global Bioanalytics, Alloy Therapeutics High-throughput polyspecificity screening by SPRi for early-stage de-risking during antibody discovery
	Abstract: In addition to having the desired interaction and mode of action on the target, therapeutic antibodies need to be highly specific. Non-polyspecificity is one of the most important characteristics to have for safety, efficacy, and ideal PK/PD. Since polyspecificity is difficult to get rid of by engineering, assessing it early in the antibody discovery process is crucial. In this study, we developed a new high-throughput SPR-based assay for polyspecificity screening. To validate the assay, we compared it to traditional assays such as ELISA or flow cytometry by using clinical stage antibodies. Where possible, results were correlated to clinical outcomes in literature. This assay is high-throughput and consumes very small amounts of sample, enabling polyspecificity de-risking at an early stage in the discovery process.
3:00pm – 3:30pm	Noah T. Ditto, Technical Product Manager, Carterra Leveraging the new Carterra LSA^XT for challenging HT-SPR applications
	Abstract: The LSA^XT expands the capabilities of HT-SPR to meet the demands of challenging assay formats. By building on the established benefits of HT-SPR including more data in less time with less sample, LSA^XT has the versatility to address a range of experimental workflows. This talk will highlight how LSA^XT is a robust platform for characterization of drug candidates including PROTAC^®s and kinase inhibitors. The benefits of enhanced sensitivity and overall data quality in LSA^XT take HT-SPR to a whole new level.
3:30pm	Symposium Ends

What You Will Learn

Register Here

Agenda